Another important phase 1 clinical trial, “Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for the Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma”, targeted relapsed/refractory ovarian cancers, including peritoneal mesothelioma, fallopian tube adenocarcinoma, adenocarcinoma of the ovary, and primary peritoneal carcinoma. The gene discussed is MSLN; the disease is peritoneal mesothelioma.